PAMS
TGTX icon

Pictet Asset Management (Switzerland)’s TG Therapeutics TGTX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$416K Buy
16,753
+1,459
+10% +$37.7K ﹤0.01% 1332
2023
Q1 		$230K Hold
15,294
– – ﹤0.01% 1660
2022
Q4 		$181K Buy
+15,294
New +$111K ﹤0.01% 1755
2022
Q2 		– Sell
-1,166,995
Closed -$11.1M – 1685
2022
Q1 		$11.1M Sell
1,166,995
-1,220,618
-51% -$14.1M 0.01% 622
2021
Q4 		$45.4M Sell
2,387,613
-59,917
-2% -$1.56M 0.05% 356
2021
Q3 		$81.5M Buy
+2,447,530
New +$75.7M 0.09% 256

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s TGTX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its TG Therapeutics (TGTX) stake by 9.5% in Q2 2023, buying an estimated $37.7K and bringing the position to 16,753 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

Pictet Asset Management (Switzerland) first reported a position in TGTX in Q3 2021 and has held it in 6 quarters since. The position peaked at $81.5M in Q3 2021. 244 funds tracked by Wall St. Rank hold TGTX as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 16,753 shares of TG Therapeutics worth $416K as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 1,459 TG Therapeutics shares in Q2 2023, an estimated $37.7K.
  • TG Therapeutics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1332 holding.
  • Pictet Asset Management (Switzerland) first reported a position in TG Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Pictet Asset Management (Switzerland)'s TG Therapeutics position peaked at $81.5M in Q3 2021.
  • 244 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.